Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects  by Nigro, Vincenzo & Piluso, Giulio
Biochimica et Biophysica Acta 1852 (2015) 585–593
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isSpectrum of muscular dystrophies associated with sarcolemmal-protein
genetic defects☆Vincenzo Nigro ⁎, Giulio Piluso
Dipartimento di Biochimica, Bioﬁsica e Patologia Generale, Seconda Università degli Studi di Napoli, via Luigi De Crecchio 7, 80138 Napoli, Italy
Telethon Institute of Genetics and Medicine (TIGEM), via Pietro Castellino 111, 80131 Napoli, Italy☆ This article is part of a Special Issue entitled: Neurom
Molecular Pathogenesis.
⁎ Corresponding author at: via Luigi De Crecchio, 7,
0815665704.
E-mail addresses: vincenzo.nigro@unina2.it, vinnigro@
http://dx.doi.org/10.1016/j.bbadis.2014.07.023
0925-4439/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 May 2014
Received in revised form 19 July 2014
Accepted 23 July 2014
Available online 30 July 2014
Keywords:
Duchenne muscular dystrophy
Dystrophin
Sarcoglycan
limb-girdle muscular dystrophy
Dysferlin
DystroglycanMuscular dystrophies are heterogeneous genetic disorders that share progressive muscle wasting. This may
generate partial impairment of motility as well as a dramatic and fatal course. Less than 30 years ago, the iden-
tiﬁcation of the genetic basis of Duchennemuscular dystrophy opened a new era. An explosion of new informa-
tion on themechanisms of disease waswitnessed, withmany thousands of publications and the characterization
of dozens of other genetic forms. Genes mutated in muscular dystrophies encode proteins of the plasma
membrane and extracellular matrix, several of which are part of the dystrophin-associated complex.
Other gene products localize at the sarcomere and Z band, or are nuclear membrane components.
In the present review, we focus on muscular dystrophies caused by defects that affect the sarcolemmal and sub-
sarcolemmal proteins.We summarize the nature of each disease, the genetic cause, and the pathogenic pathways
that may suggest future treatment options. We examine X-linked Duchenne and Becker muscular dystrophies and
the autosomal recessive limb-girdle muscular dystrophies caused by mutations in genes encoding sarcolemmal
proteins. The mechanism of muscle damage is reviewed starting from disarray of the shock-absorbing
dystrophin-associated complex at the sarcolemma and activation of inﬂammatory response up to the ﬁnal stages
of ﬁbrosis. We trace only a part of the biochemical, physiopathological and clinical aspects of muscular dystrophy
to avoid a lengthy list of different and conﬂicting observations. We attempt to provide a critical synthesis of what
we consider important aspects to better understand the disease. In our opinion, it is becoming evermore important
to go back to the bedside to validate and then translate each proposed mechanism. This article is part of a Special
Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. IntroductionThe terms “progressive” or “pseudo-hypertrophic” muscular
dystrophy appeared in the literature in the early 1900s. The deﬁnition
“progressive muscular dystrophy of childhood” [1] was then adopted
to indicate the least benign form of muscular dystrophy characterized
by childhood-onset, X-linked inheritance, wasting and weakness of
the muscles, and pseudo-hypertrophy of the gastrocnemius. At that
time, genetic heterogeneity only consisted in a distinction with the
facio-scapulo-humeral type showing autosomal dominant transmission
[2]. The term “Duchenne-type” appeared at the end of the 1950s, after
the re-discovery of papers dated 1868 of the great French neurologist
Duchenne deBoulogne (1806–1875). Thiswasnot theﬁrst report, how-
ever, since Edward Meryon [3,4] and Gaetano Conte [5] had already
published their work, in 1851 and 1836, respectively.uscular Diseases: Pathology and
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gmail.com (V. Nigro).In 1985,Monaco and Kunkel identiﬁed distinct large deletions in the
Xp21 region associated with Duchenne muscular dystrophy (DMD) [6].
For the ﬁrst time they used the “reverse genetics” approach that
searches for new genes from their chromosomal position without any
prior functional data [7]. From the characterization of the DMD locus
product, dystrophin [8], and its localization at the sarcolemma [9], a
new era was opened and the dystrophin-associated protein complex
was isolated and characterized [10–12]. A number of new sarcolemmal
proteinswere associatedwith othermuscular disorders.Mutations of any
of the four dystrophin-associated sarcoglycan subunits were associated
with autosomal recessive limb-girdle muscular dystrophies (LGMD)
[13–17], while mutations in the laminin α 2-chain gene (LAMA2) were
associated with merosin-deﬁcient congenital muscular dystrophy [18].
Αlpha- and beta-dystroglycan were found to be central members the
skeletal muscle dystrophin glycoprotein complex, linking dystrophin to
proteins in the extracellular matrix. The intricate glycosylation steps
that enable α-dystroglycan to interact with laminins, agrin and perlecan
were further highlighted by the identiﬁcation of about 15 neuromus-
cular disorders due to reduced dystroglycan glycosylation [19,20].
The dystrophin-associated complexmaybe considered as a functional en-
tity with the role of reinforcing the plasma membrane during eccentric
muscle contractions. Othermuscular dystrophies are causedbymutations
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brane re-sealing following injury, such as the dysferlin gene. Caveolin-3
deﬁciency, although sarcolemmal, is not included in this review, since it
involves an alteration of vesicular trafﬁcking that may be better asso-
ciated with a distinct pathogenesis. Other non-sarcolemmal causes
of LGMD have been recently reviewed [21].
1.1. Duchenne muscular dystrophy
Both the historical terms progressive and pseudohypertrophic are
appropriate for Duchenne Muscular Dystrophy (DMD, MIM 310200).
DMD has a childhood onset and a prevalence of 1 in 3,500 boys world-
wide. Clinical symptoms of DMD are not present at birth. Diagnosis is
usually made at 5 years of age, although serum enzymes derived from
muscle membrane leakage (creatine kinase, transaminases, lactate
dehydrogenase, aldolase) are extremely high since birth. Infants with
serum creatine kinase levels above 2000 IU/l are 0.03% of the total popu-
lation, but have high chance of being affected by DMD or LGMDs [22]. To
reduce the diagnostic delay enabling earlier treatments, newborn screen-
ing has been considered [23] by taking a drop of blood from the heel of
each child 24–48 hours after birth to test the level of creatine kinase.
Despite advances in diagnostic testing, the average age of diagnosis
is 5 years, when the ﬁrst clinical signs of DMD usually occur with a
symmetrical weakening of the gluteal and quadriceps muscles. The
most obvious consequence is a lordotic posture and difﬁculty in
climbing stairs or in getting up from a squatted position. Classically,
the child rises from the ground assuming a prone position with the
arms on the quadriceps "climbing up" on himself (Gowers' maneuver).
Total muscle force growsmore slowly in DMD boys than their peers, and
then begins to decrease starting from 7–8 years of age [24]. Weakness
and joint contractures result in the loss of ambulation within 13 years.
Typical, but non-speciﬁc for DMD, is the pseudohypertrophy of calves, as-
sociated with fatty inﬁltration of the soleus and gastrocnemius muscles.
The weakness of the diaphragm and intercostal muscles as well as chest
deformities leads to progressive reduction in vital capacity. Heart is
often co-involved in themajority of patients [25]. Itwas recently reported
that the prevalence of cardiomyopathy in 340 patients (aged 2–28 years)
was 27% [26]. DMD boys show common reduced verbal ability with
attention deﬁcit: about 20% of cases present a more pronounced delay
in learning and/or autistic behavior. Life expectancy has increased in re-
cent years up to 40 years of age and this may be the result of improved
management of respiratory and cardiac complications [27–29].
Becker muscular dystrophy (BMD, OMIM 300376) is apparently less
frequent (1:11,500 males) than DMD, clinically milder, and more
variable. BMD has later onset and a longer life expectancy. The gait
may be waddling, although conserved until adulthood. BMD patients
also show weakness of skeletal and respiratory muscles and dilated
cardiomyopathy. There is also an X-linked dilated cardiomyopathy
(XLDC), a condition characterized by exclusive cardiac dystrophin
involvement [30].
2. Molecular genetics and testing
DMD and BMD are allelic muscular dystrophies caused by different
mutations in the dystrophin (DMD) gene. This spans 2.22 Mb of DNA
on the short arm of X-chromosome (Xp21) in a G-band, an A/T-rich re-
gion at low gene density. The DMD gene has in fact average-size exons
separated by giant introns. Furthermore, theDMD gene has a high intra-
genic recombination rate of over 12 cM [31]. The DMD gene is so huge
(the largest in the human genome) that each RNA molecule requires
16 hours of transcription [32], duringwhich a co-transcriptional splicing
generates a major mRNA species composed of 79 exons. Many non-
coding RNAs are produced from the DMD locus, such as circular mole-
cules of RNA [33] or long non-coding RNA [34]. There are at least four
promoters at the 5' of the gene encoding a full-length dystrophin,
while the internal promoters generate four shorter non-muscle isoforms,such as Dp260, Dp140, Dp116 and Dp71. The 14 kb-transcript is
expressed in skeletal and cardiac muscle and, in smaller amounts, in
the brain. It encodes for a rod-shaped dystrophin of 427 kDa [8,35].
DMD is caused by a category of mutations that make impossible to
encode a functional dystrophin. Thus, the absence of dystrophin is the
hallmark of DMD. BMD is more heterogeneous, since it is associated
with distinctive gene defects that permit the synthesis of reduced
amounts of qualitatively abnormal dystrophin. In addition to mini-
dystrophins, maxi-dystrophins are also rarely observed. Compared
with the 100% function of full-length dystrophin, these shorter isoforms
should be in the functional range between5% and 20%. Indeed, about 30%
of full-length dystrophin is sufﬁcient to avoid muscular dystrophy [36].
This indicates that some DMD gene defects with N30% of dystrophin
can also be found in normal subjects [37]. Unlike the majority of other
genes, large intragenic deletions account for ~65% of cases, and duplica-
tions for 10 %. These mutations are mainly located in two hotspots, the
principal being at the 3' of the gene (exons 44–53) and the other at the
5' (exons 3–19). The largest database of dystrophin mutations can be
found at www.dmd.nl [38]. Small mutations [39,40], consisting of non-
sense mutations [41], insertions or deletions of a base and mutations of
the splicing sites are relatively less frequent (23%). These are private
and distributed throughout the cDNA, although mutations downstream
of exon 74 are usually associated with BMD. As a rule, most point
mutations in BMD affect splicing sites that allow a partial production of
dystrophin [42]. The causative missense mutations mainly in the ZZ
domain [43] are extremely rare, while a large number of amino acid
variants of dystrophin are also found in healthy subjects. About 2% of
DMD patients carry elusive mutations, such as deep intronic mutations
or inversions. Deletions and duplications may be easily diagnosed in
patients and carriers fromperipheral bloodDNA samples using quantita-
tive techniques such as Log-PCR [44], MLPA [45,46] or custom array-
comparative genomic hybridization [47–50]. The diagnosis of point mu-
tations requires sequencing of cDNA from muscle biopsy, while for the
use of next-generation sequencing (NGS) whole exome approach is
justiﬁed only in the differential diagnosis [51]. To distinguish between
BMD and DMD it may be important to check whether the residual
frame mRNA is maintained after the deletion (Monaco’s rule) [52]. The
preservation of an open reading frame will allow the translation of a
mini-dystrophin with a shortened rod domain. Even in the absence of
unbalanced X inactivation, a heterozygous carrier of a mutation in the
DMD gene may develop a cardiomyopathy [53].
3. Dystrophin
Dystrophin is a low abundance protein, accounting for approximately
75 mg/kg of muscle in healthy individuals (0.002% of the total striated
muscle protein) [54]. Even if the amount of dystrophin is small, its role
is crucial for the maintenance of muscle integrity. Dystrophin is a cyto-
skeletal protein located on the cytoplasmic side of the sarcolemma and
forms a mechanically strong connection between the sarcolemma and
the costameric cytoskeleton. This stabilizes cells by linking actin ﬁla-
ments, intermediate ﬁlaments, and microtubules to transmembrane
complexes [55,56]. In dystrophin, we distinguish four functional do-
mains: 1) the actin-binding domain: amino acids 14–240, (exons
2–8); 2) the large central rod-like domain consisting of 24 repeat
units: aa 253–3040, (exons 8–61); 3) the cysteine-rich domain that
binds β-dystroglycan: aa 3080–3360 (exons 62–69); 4) the unique
C-terminal domain that interacts with dystrobrevin and syntrophins:
aa 3361–3685 (exons 69–79). An additional binding site for actin is
mapped in the middle of the rod [57]. Furthermore, spectrin-like re-
peats 16 and 17 (R16/R17) of the rod domain can bind nNOS [58,59].
This observation suggests that not only α1-syntrophin [60,61], but
also dystrophin directly contributes to the sarcolemmal localization of
nNOS [58].
Dystrophin is part of a large protein complex, the dystrophin-
glycoprotein complex (DGC). Dystroglycan is the central protein of
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basal lamina through α-dystroglycan and to dystrophin inside the cell
through β-dystroglycan. The glycosylated α-dystroglycan binds
laminin-211 [62] in the extracellular matrix and completes the bridge
of muscle stability. α-, β-, γ-, and δ-sarcoglycan, α-dystrobrevin,
syntrophins and sarcospan are essential components of DGC (Fig. 1).4. Sarcoglycanopathies
Mutations in several components of DGC and other constituents
associated with muscle membrane are the cause of other forms of
inherited muscular dystrophy or congenital muscular dystrophies.
The sarcoglycans are single transmembrane domain-containing
proteins that are N-glycosylated on their larger extracellular domain.
Post-translational processing of the sarcoglycan complex is necessary
for proper functioning of DGC. Each sarcoglycan is glycosylated
on asparagine residues, whereas nonglycosylated forms of β- and
δ-sarcoglycan fold incorrectly, mislocalize and aggregate. The genes in-
volved in their glycosylation are still unknown. Sarcoglycan proteins
form a heterotetrameric complex linked to the dystrophin-dystroglycan
axis [63]. Autosomal recessive LGMDs 2C-2F are caused byprimarymuta-
tions in any of four genes encoding sarcoglycan complex subunits:
LGMD2C (γ-sarcoglycan) [15], LGMD2D (α-sarcoglycan) [16], LGMD2E
(β-sarcoglycan) [13,17], and LGMD2F (δ-sarcoglycan) [14,64]. There
are two other non skeletal muscle sarcoglycans: ε-sarcoglycan, which
is mutated in myoclonus dystonia [65] and ζ-sarcoglycan [66], which
is homologous to γ- and δ-sarcoglycan, only expressed in brain and
cerebellum.
Assembly of the sarcoglycan complex in skeletal muscle has been
studied in vivo and in vitro [11]. The sarcoglycan core is formed by the
basic proteins β- and δ-sarcoglycan that are assembled ﬁrst, followed
by the inclusion ofγ-sarcoglycan and thenα-sarcoglycan. In the smooth
muscle, the sarcoglycan complex contains the ε-sarcoglycan instead of
α-sarcoglycan, while in the heart the sarcoglycan complex comprises
both types. The complete sarcoglycan complex then associates with the
dystroglycan complex and sarcospan, and is delivered to the membrane
apparently through vesicular transport along microtubule networks
[67]. Synthesis of dystrophin occurs independently and this is consistentFig. 1. Schematic representation of dystrophin-glycoprotein complex (DGC) andwith the observation that dystrophin is present even in the absence of the
sarcoglycan complex.
In case of a mutant sarcoglycan that fail to pass quality control in the
endoplasmic reticulum (ER), it will be dislocated into the cytosol and
degraded by the proteasome. Unlike others, α-sarcoglycan may be able
to translocate alone to the plasma membrane after leaving the Golgi
[68]. When disease is only caused by mislocation of α-sarcoglycan,
targeted drugsmay theoretically be used to rescue LGMD2D [69]. In con-
trast, when β-sarcoglycan or δ-sarcoglycan are absent, no sub-portions of
the sarcoglycan complex are found at the sarcolemma.Muscle biopsies of
patients with some missense mutations of α-sarcoglycan show only a
reduction of the remaining sarcoglycans, β-, γ-, and δ-. Presence of
β-, α-, and δ-sarcoglycan may also occur with some mutations of
γ-sarcoglycan. When the sarcoglycan complex is absent from the
skeletal muscle, dystrophin is only minimally affected. However, dys-
trophin absence is followed by a marked reduction of the sarcoglycan
complex at the sarcolemma. This reduction of sarcoglycan is also seen
in the mdx mouse, a naturally occurring spontaneous mutant that
serves as a model of DMD. Inmousemodel ofα-sarcoglycan deﬁciency,
the cardiac sarcoglycan complex and the dystrophin-dystroglycan are
mildly reduced, unless the ε-sarcoglycan is also lacking [70]. The
sarcoglycanopathies are typically forms of LGMDs with childhood onset.
Mutations in any of the four sarcoglycan genes (sarcoglycanopathies)
constitute about 10-15% of all LGMD2s [63,71,72], but 68% of the severe
forms [73]. LGMD2D is the most prevalent, but LGMD2C is common in
the Maghreb and India [74] for the high allele frequency of 525delT
and in Gypsies for the Cys283Tyr allele [75]. The clinical proﬁle of
sarcoglycanopathies is heterogeneous with both severe and mild
forms, which are also found in the same families [76]. In general,
the disease is more severe and rapid than in other LGMDs. The typical
form has a childhood onset usually with quadriceps muscle wasting.
Cardiomyopathy may occur in all forms [77,78], but rarely in LGMD2D.
In animal models, δ-sarcoglycan mutations are associated with cardio-
myopathy [79,80].
DMD and sarcoglycanopathies share the sarcoglycan loss, which is
primary and secondary, respectively. Mouse models have helped to
understand whether the loss of sarcoglycan is a key step for membrane
instability and whether the restoration of the sarcoglycan complex
alone may be useful to prevent muscular dystrophy.of other sarcoplasmic associated proteins involved in muscular dystrophies.
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Dp260 in the mdx dystrophin-deﬁcient background was generated
[81]. The overexpression of Dp260 was important for costameric assem-
bly of the dystrophin-glycoprotein complex, including sarcoglycan and
dystroglycan, but themice presented the same reductions in force gener-
ation of mdxmuscles. These data suggest that when the DGC is present
and properly localized, it provides protection from contraction-induced
injury, but this is not sufﬁcient to prevent the dystrophic process in the
lack of the N terminus of dystrophin, which may have a second nonme-
chanical function. Increased muscle mass and total force were obtained
with the overexpression of a shorter form of dystrophin, Dp116, in the
skeletal muscle of severely affected dystrophin/utrophin gene double
knock-out mice [82]. Although this animal model is very prone to spec-
tacular phenotypic rescues with many other treatments, these data indi-
cate that the lack of dystrophin may damage two separate functions:
i) the assembly of DGC (sarcoglycan and dystroglycan), which is critical
for growth and maintenance of muscle mass; ii) a linkage between the
extracellular matrix and the actin cytoskeleton, which is able to prevent
dystrophic pathophysiology.
5. Dystroglycanopathies
Dystroglycan is produced as a single polypeptide from the DAG1
gene that is subsequently cleaved into α- and β- subunits at residue
653.α/β-dystroglycan is not only a protein of DGC, but is mostly associ-
ated in nonmuscle tissues with other extracellular matrix proteins. It
appears that even in muscle a signiﬁcant fraction of dystroglycan does
not directly associate with dystrophin or utrophin (dystrophin homo-
log), but is part of separate protein complexes distinct from DGC [83].
The absence of dystroglycan is embryonically lethal in mice due to the
disruption of Reichert's membrane [84]. For a review of the numerous
roles of dystroglycan see [85].
One single missense mutation in the dystroglycan gene causing
LGMD2P has so far been identiﬁed [86,87]. Recent advances have
highlighted the importance of post-translational processing for the
interaction of dystroglycanwith its ligands. A very large number ofmus-
cle and brain disorders are, in fact, caused bymutations in genes that are
directly or indirectly responsible for the glycosylation ofα-dystroglycan
and studies on these conditions have provided insights into its crucial
steps. Dystroglycan undergoes both asparagine (N)-linked and serine/
threonine (O)-linked glycosylation as part of its normal processing.
There are three N-linked glycosylation sites on α-dystroglycan and ap-
proximately 50 O-linked glycosylation sites. Most dystroglycanopathies
are associated with hypoglycosylation of α-dystroglycan, which can be
seen in bothmuscle and brain.Mutations inmany genes cause secondary
dystroglycanopathies. POMT1, POMT2 and POMGnT1 encode proteins
involved in the mannosylation of serine or threonine residues of
α-dystroglycan by means of an O-linkage [85]. FKTN, FKRP and GTDC2
encode glycosyltransferases on the basis of sequence homology. The
DPM1 [88], DPM2 [89], and DPM3 [90] genes encode subunits of the
dolichol-phosphate-mannose (DPM) synthase. DOLK encodes dolichol
kinase responsible for formation of dolichol-phosphate and its muta-
tions cause dilated cardiomyopathy [91]. LARGE encodes for a bifunc-
tional enzyme, the Like-acetylglucosaminyltransferase. Interestingly,
expression of LARGE strongly enhances the laminin binding activity of
α-dystroglycan. For this reason, its up-regulation has been claimed to
be one of themost promising possible therapies formuscular dystrophy
[92,93]. However, recent data indicate that there is a worsening of
muscular dystrophy [94,95]. B3GNT1 and B3GALNT2 code for new glyco-
syltransferase. Finally, mutations in the ISPD, TMEM5 and GMPPB genes
also cause dystroglycanopathies [20].
In humans, mutations affecting the glycosylation of dystroglycan
result in disorders such as congenital muscular dystrophies, muscle-
eye-brain disease (MEB), and Walker-Warburg syndrome (WWS).
From a clinical point of view, dystroglycanopathies may be very severe
conditions in which syndromes include severe malformations of thebrain and eye. There is also the possibility of milder muscular pheno-
types associatedwithmutations of the same genes. In genotype/pheno-
type correlation it is crucial to take into account the residual enzyme
activity of the mutated gene product. A severe or lethal phenotype
may be observed in the case of homozygosity for null alleles [19]. Alter-
natively, the presence of hypomorphic alleles, consisting of amino acid
substitutions that do not completely inactivate the enzyme activity,
conﬁnes the clinical proﬁle to skeletal muscle, milder and classiﬁed as
LGMD. The most frequent LGMD gene in this group is FKRP, which
causes LGMD2I. In some countries (UK, Denmark, and Norway)
LGMD2I is relatively common, for the high carrier frequency of the
Leu276Ile allele (1:116). LGMD2I may be clinically similar to BMD,
with a late-childhood onset, calf hypertrophy, high serum CK, and
cardiomyopathy and respiratory impairment that may prevail.
6. Dysferlinopathy
Dysferlin is a sarcolemmal protein that may be deﬁcient in a form of
LGMDs (LGMD2B). LGMD2B is the second form in order of frequency
(about 15–25%) in many geographical areas [96–98], but not every-
where [99]. Dysferlin is a ubiquitous 230-KDa transmembrane protein
involved in calcium-mediated sarcolemma resealing [100]. Although
muscle inﬂammation is widely recognized in dysferlinopathy and
dysferlin iswell expressed inmonocytes, the role of the immune system
to the pathology remains obscure. Muscle of dysferlinopathy patients is
characterized bymassive immune cell inﬁltrates, and dysferlin-negative
monocytes were shown to be more aggressive, but macrophages show
altered adhesion and motility [101]. DYSF mutations are associated
with mixed clinical presentations including severe functional disability
to mild late-onset forms [102,103]. About 25% of cases may be clinically
misdiagnosed as havingpolymyositis [104]. The samemutations cause a
distal myopathy, known as Miyoshi myopathy type 1 (MM1) [105].
However, classiﬁcation of separate clinical phenotypes ismore apparent
than real and is not justiﬁed by pathological differences [106].
Some patients were very athletic before the onset of symptoms [107]
and this suggests that a competitive physical activitymaymodify the pen-
etrance of DYSFmutations. Regeneration seems to be attenuated [108].
Dysferlin has a crucial role in muscle repair [109] and this will promote
strategies to facilitate membrane resealing in dysferlinopathy [110].
7. Mechanisms of muscle damage
The biochemical cause of DMD is the absence of a functional dystro-
phin,which results in the reduction or complete absence of the remaining
DGC components from muscle membrane, and disarray of the shock-
absorbing connection at the sarcolemma. Furthermore, the loss of DGC-
actin axis causes a threefold decrease in muscle elasticity in mice [111,
112]. This destabilizes the transmission of lateral force, boosting the num-
ber and size of sarcolemmal micro-tears mainly caused by lengthening
(eccentric) muscle contractions [113] (Fig. 2A). This explains why large
and non-hydrophobic muscle proteins can traverse the lipid bilayer and
increased serum activities are detected. In normal subjects, micro-tears
are typically associatedwith inﬂammation and elayed onset muscle sore-
ness [114]. In normal muscle regeneration, any transient inﬂammatory
response is followed by the activation and proliferation of myoblasts
that differentiate into myocytes, and fuse to form myoﬁbers, typically
with centralized nuclei, resulting in repair. In general, micro-tear forma-
tion and repair of the lipid bilayer also occur repeatedly in DMD, but
with time, they eventually produce degeneration of the muscle ﬁber. In
this case, the inﬂammatory response becomes chronic and damaging.
There is general agreement on the hypothesis of Ca2+ ion entry into
the cytoplasm throughmicro-tears and probably through active calcium
channels [115,116] (Fig. 2B). Mice overexpressing transient receptor
potential canonical 3 (TRPC3) develop biochemical signatures of
myoﬁber degeneration and regeneration, inﬁltration of immune cells,
and ﬁbrosis, suggesting that lifelong Ca2+ increase may induce some
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Fig. 2. Sarcolemmal micro-tears (A) concur with sarcoplasmic reticulum leaking (B) in determining Ca2+ ions inﬂux.
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functional ischemia from the loss of nNOS at the sarcolemma could ex-
plainwhyDMDchildrenmay suffer fromnocturnalmuscle cramps after
major daily movements. Calcium entry will activate calpains and per-
turb the homeostasis of muscle proteins leading to ﬁber degeneration
and death. Although overexpression of the calpain inhibitor, calpastatin,
may reduce the dystrophic process in mdxmice [118], it is simplistic to
consider proteolysis by calpain as directly responsible formuscle atrophy,
sincemany othermechanisms remain to be clariﬁed. Fibersmay undergo
necrosis by excessive calcium inﬂux and this triggers key damage path-
ways that progress towards the progressive replacement of affectedmus-
cle with connective and adipose tissue.
Claims about the key pathways that precede and/or promote muscu-
lar dystrophy involve abnormal signaling, oxidative stress, inﬂammatory
response, autophagy dysregulation, apoptosis, and ﬁbrotic response.
All these studiesmay have some intrinsic limitations such as the bio-
chemical methods applied to cells that cannot explain working-muscle
physiology and preferential damage in some muscles. In addition, the
widely used mdx mouse is only dystrophin-deﬁcient, but not affected
by DMD. Mdx mouse muscle shows a higher regenerative capacity
that ensures a more benign phenotype and essentially normal function.
Some pathways are not shared, such as the activation of calcineurin/
NFAT pathway [119], which is not active in DMD [120] together with
other important differences [121].
The ﬁrst claim to be proved is the additional roles of dystrophin
and the glycoproteins as signalingmolecules [122]. The claim derives
from the early alteration of many signaling pathways in DMD [123].
Aberrant signaling eventually results in altered myogenic expression
and pathology in muscular dystrophy, but it is difﬁcult to distinguish
between causes and effects.
Nitric oxide (NO) is a signaling molecule that regulates different
skeletal muscle functions, such as force production, the maintaining of
an adequate blood ﬂow during contraction, respiration and glucose
homeostasis [124]. In DMD patients and dystrophic animal models,
the loss of DGC integrity delocalizes nNOS from the sarcolemma and it
appears diffusely reduced in the cytosol [125–127]. As previouslydiscussed, the R16/17 spectrine-like motifs within rod domain concur
with syntrophin to the sarcolemmal localization of nNOS [58–61]. A
most severe phenotype has been observed in BMDpatients carrying de-
letions of exons encoding R16/17 motifs within rod domain [128–130].
Therefore, nNOS mislocalization greatly contributes to the dystrophic
phenotype by inducing functional ischemia [131–133], by impairing
satellite cell activation and by increasing fatigue-mediated injury, as
well as by increasing oxidative stress and inﬂammation [134,135].
However, little doubt remains as to the importance of the inﬂamma-
tory response in muscular dystrophy. Neutrophils, macrophages and T
cells inﬁltratemuscle at stages that anticipate the onset of clinical disease.
Inﬂammation never stops, but persists until muscle tissue is present.
Inﬂammation may be considered as the central process that contributes
tomuscle lesion formation and progression. In particular, the balance be-
tween proinﬂammatorymacrophagesM1 and anti-inﬂammatorymacro-
phagesM2 is critical for the degeneration/regeneration ofmuscle (Fig. 3).
Inmuscular dystrophy, the residentmononuclear phagocyte populations
cannot adequately respond to tissue stress and waves of recruitment of
monocytes enter the injured muscle and differentiate into a spectrum
of mononuclear phagocytes. The newly recruited cells are proinﬂamma-
tory and secrete pro-inﬂammatory mediators such as tumor necrosis
factor (TNF), nitric oxide (ΝΟ) and IL-1. Othermediators produced by ac-
tivated macrophages include IL-12 and IL-23, which are decisive in
inﬂuencing the polarization of TH1 cells, which further drive inﬂammato-
ry responses forward. Furthermore,macrophages can cause phagocytosis
of injured myoﬁbers and then present antigens to T cells to induce their
activation. Activatedmacrophages produce reactive oxygen and nitrogen
intermediates, including NO and superoxide, which are toxic for neigh-
boring tissues and lead to aberrant inﬂammation. Indeed, M1 macro-
phages must be limited to avoid extensive tissue damage, while M2
macrophages exhibit potent anti-inﬂammatory activity and have impor-
tant roles in wound healing and ﬁbrosis (Fig. 3). M2 macrophages also
antagonize M1 responses, which may be crucial for wound healing and
restoration of muscle tissue stimulating the proliferation of satellite
cells [136]. TNF-α and IFN-γ are two inﬂammatory cytokines produced
by bothM1macrophages and skeletal muscle cells that inhibit transition
Fig. 3. The role of M1 and M2 macrophages in muscle injury and regeneration, as well as in promoting ﬁbrosis.
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as IL-4 and IL-10 promote activation of M2 macrophages in the form of
M2a and M2c [136]. Accordingly, treatment ofmdxmice with IL-10 im-
proved the histological features by deactivating M1 macrophages and
promoting regeneration [137,138], while genetic ablation of the IL10
gene caused extensive inﬁltrates of pro-inﬂammatory M1 macrophages
inmdxmice with major cardiac and respiratory dysfunction [139].
These immune response-related aspects could be associated with
the clinical beneﬁts produced by the use of steroid in DMD. Steroids
are used worldwide to improve muscle strength, increase muscle
mass, and slow the progression of the disease [140,141]. Nevertheless,
the mechanism of action of steroids in dystrophin deﬁciency is well be-
yond their role in immune response, involving membrane effects and
multiple levels of regulation [142,143]. The over-simpliﬁed equation
“stronger immune response/more dystrophy” has promoted other im-
munosuppressive approaches to treat DMD. However, an important
clinical trial using cyclosporin A for treatment of a large number of
DMD boys did not show any signiﬁcant improvement in primary out-
come measures and no major improvement in pathology [144,145].
The fatal destiny of muscular dystrophy is the commitment towards
the progressive ﬁbrosis that impairs any residual muscle force and
elasticity. In addition, ﬁbrosis affects the vital functions and is the
major problem for future treatments based either on stem cell or gene
delivery. Fibrosis occurs as the outcome of a chronic inﬂammation
process and necessarily involves the TGFβ pathways [146] (Fig. 3). How-
ever, inﬂammatory response and overexpression of proteins such as
transforming growth factor-beta1 (TGF-β1) and myostatin, promote
the formation of ﬁbrotic tissue to replace damaged myoﬁbers. Drug
targeting of the TGFβ pathways is, promisingly, within reach [147].
Genetic background can also modify the ﬁbrotic response, such as
polymorphisms of the latent TGFβ binding protein 4 gene (LTBP4)
[148]. Recently, it has been demonstrated that ﬁbro-adipogenic progen-
itors may choose to support muscle regeneration or promote ﬁbro-
adipogenic degeneration and that HDAC inhibitors may de-repress a
latent myogenic program in youngmdxmice [149].
8. Conclusions and promises
Within the DGC, the sarcoglycan complex, α/β-dystroglycan and
dystrophin are interconnected at multiple levels including post-translational processing, trafﬁcking to the membrane and during their
more stable interaction at the membrane. Mutations in genes that are
part of this complex affect the muscle stability.
Genetic and stem cell therapy approaches are being pursued in
animal models of muscular dystrophies [150]. The sarcoglycanopathies
are at the forefront of experimentingwith gene therapy protocols using
adeno-associated viruses (AAVs), because cDNAs are all small in size
and, most importantly, they work in animal models [151] including
the four KOmice and BIO14.6 cardiomyopathic hamster (δ –sarcoglycan
deﬁcient) [79]. Micro-dystrophin has been successful delivered through
AAV into dystrophic dogs [152].
For DMD, one encouraging advance has been the targeting of RNA of
dystrophin by antisense oligonucleotides to induce exon skipping in
boys with out-of frame deletions [153]. The strategy aims to restore
the open reading frame and generate minidystrophins (BMD-like).
This has progressed rapidly to phase 3 clinical trials [154]. Similar
approaches are being explored in other genetic disorders, such as myo-
tonic dystrophy, dysferlinopathies, and motor neuron diseases [155].
Numerous pharmacological approaches that interfere with the
secondary processes involved in dystrophic progression are effective
in preclinical models and many drugs are under study. These efforts
will raise more hopes for muscular dystrophy patients.
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